Pharma major plummets over 10% after third trial disappointment in a week

Novartis shares fell more than 10 percent on Tuesday following the release of trial results for del-desiran. The company did not immediately issue a statement regarding the trial outcome. This was Novartis's third unsuccessful trial result within seven days, according to the company's disclosures.

Next story